Journal article icon

Journal article

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial

Abstract:

As part of the UK NCRI AML17 trial, adult acute myeloid leukaemia patients in remission could be randomised to receive the mTOR inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive everolimus or not for a maximum of 84 days between chemotherapy courses. The primary endpoint was relapse free survival (RFS). At 5 years there was no difference in Relapse Free Survival (29% vs 40%; OR 1.19 (0.9-1.59) p=0.2), c...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.3324/haematol.2018.189514

Authors


Burnett, AK More by this author
Knapper, S More by this author
Sweeney, M More by this author
Expand authors...
More from this funder
Grant:
*Grant Number Example*
Publisher:
Ferrata Storti Foundation Publisher's website
Journal:
Haematologica Journal website
Volume:
103
Issue:
10
Pages:
1654-1661
Publication date:
2018-07-05
Acceptance date:
2018-07-04
DOI:
EISSN:
1592-8721
ISSN:
0390-6078
Pubs id:
pubs:930208
URN:
uri:70774aac-abe1-41a5-9922-be66b7ed7364
UUID:
uuid:70774aac-abe1-41a5-9922-be66b7ed7364
Local pid:
pubs:930208
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP